Pattern Bioscience

Pattern Bioscience is a privately held in vitro diagnostics company founded in 2016 to help address the antibiotic resistance problem. Pattern is developing a next-generation clinical microbiology platform based on its patented phenotypic single-cell technology that rapidly identifies pathogens and determines their antibiotic response without the need for traditional time-consuming culture steps. Pattern's Digital CultureTM technology relies on functional endpoints covering all possible resistance mechanisms, offering a more comprehensive and reliable diagnosis compared to rapid genotypic tests. The platform will provide more reliable diagnoses faster than the current standard of care.